Sanofi (SNY)
NASDAQ: SNY · Real-Time Price · USD
50.74
0.00 (0.00%)
At close: Jan 17, 2025, 4:00 PM
50.73
-0.01 (-0.02%)
After-hours: Jan 17, 2025, 4:26 PM EST
Sanofi Revenue
Sanofi had revenue of 14.16B EUR in the quarter ending September 30, 2024, with 11.49% growth. This brings the company's revenue in the last twelve months to 48.45B, up 6.01% year-over-year. In the year 2023, Sanofi had annual revenue of 46.03B with 1.42% growth.
Revenue (ttm)
48.45B EUR
Revenue Growth
+6.01%
P/S Ratio
n/a
Revenue / Employee
562,738 EUR
Employees
86,088
Market Cap
128.27B USD
Revenue Chart
* This company reports financials in EUR.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 46.03B | 644.00M | 1.42% |
Dec 31, 2022 | 45.39B | 6.21B | 15.86% |
Dec 31, 2021 | 39.18B | 1.81B | 4.83% |
Dec 31, 2020 | 37.37B | -262.00M | -0.70% |
Dec 31, 2019 | 37.63B | 1.95B | 5.48% |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Dec 31, 2014 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 400.28B |
Johnson & Johnson | 87.70B |
Merck & Co. | 63.17B |
AbbVie | 55.53B |
AstraZeneca | 51.21B |
Novartis AG | 49.94B |
Thermo Fisher Scientific | 42.37B |
Abbott Laboratories | 41.22B |
SNY News
- 1 day ago - Top 4 Immunology Stocks Poised For Growth In 2025 - Seeking Alpha
- 6 days ago - Sanofi (SYN) CEO Paul Hudson Hosts 43rd Annual J.P. Morgan Healthcare (Transcript) - Seeking Alpha
- 7 days ago - Top 5 Cancer Pharma Stocks With Strong Risk/Reward In 2025 - Seeking Alpha
- 7 days ago - Scribe Therapeutics Achieves Milestone for In Vivo Program in Collaboration with Sanofi - Business Wire
- 7 days ago - Press Release: Sarclisa obtains first approval in China for the treatment of adult patients with relapsed or refractory multiple myeloma - GlobeNewsWire
- 10 days ago - Sanofi: Underappreciated Powerhouse Primed For Long-Term Growth (Rating Upgrade) - Seeking Alpha
- 11 days ago - Press Release: New Sarclisa subcutaneous formulation met co-primary endpoints in the IRAKLIA phase 3 study in multiple myeloma - GlobeNewsWire
- 13 days ago - Alloy Therapeutics Announces a Target Specific Collaboration and License Agreement for use of AntiClastic™ Antisense Platform with Sanofi - Business Wire